Approximately 1 in 10 transcatheter aortic valve replacement (TAVR) procedures in the U.S. were for an off-label indication, with similar 1-year mortality rates compared to on-label use, suggesting that TAVR may be a possible procedure option for certain patients requiring a heart valve replacement, according to a study published by JAMA Cardiology.
↧